Гинекология (Oct 2015)
A meta-analysis of clinical studies on the use of iron fumarate for the prevention and treatment of iron deficiency anemia in pregnant women
Abstract
Iron fumarate, especially in combination with vitamins is an important form of iron for use in the therapy and prophylaxis of iron deficiency anemia (IDA) in women of reproductive age. The results of a meta-analysis of 11 clinical trials of drugs iron fumarate, have incorporated in a total of 473 patients in the "Case" (receiving iron fumarate) and 470 in the group "Control". The average age of study participants was 30±5 years; patients took drugs based on iron fumarate at a dose of 20 to 150 mg/day, based on elemental iron: an average of 58±21 mg/day, where 58 mg/day - average value (M), and 21 mg/day - the standard deviation (m). Preparations were made for 41±25 days. In 10 of the 11 studies used the drug on the basis of iron fumarate - Ferretab. Meta-analysis of the association between the drug intake and the risk of Ferretab various pathological states allowed to establish a significant decrease in the risk of iron deficiency anemia by 71% (RR 0.29, 95% CI 0.21-0.42, p=6.9¥10-11), the risk microcytosis - by 68% (RR 0.32, 95% CI 0.20-0.50, p=1.2¥10-5), the risk of reduced (less than 110 g/L) hemoglobin levels - by 62% (RR 0.38, 95% CI 0.20-0.50; p=1.1¥10-3) reduced the risk (less than 20 g/L) ferritin levels - by 63% (RR 0.37, 95% CI 0.24-0.56; p=7.1¥10-5) and reduced the risk (less than 20 mmol/liter) levels of serum iron - by 71% (RR 0.29, 95% CI 0.19-0.45; p=5.3¥10-7). Levels of serum iron and ferritin - the generally accepted criteria for evaluating the effectiveness of treatment of IDA. The side effects associated with Ferretab intake were not ascertained, including those of the gastrointestinal tract. Thus, this meta-analysis suggests that the drug Ferretab is effective and safe for the treatment of iron deficiency states.
